Abstract
Endocrine and metabolic disorders, chronic inflammatory conditions, advanced maternal age, obesity, and unhealthy lifestyle habits can impair reproductive potential by promoting oxidative stress, chronic inflammation, and hyperinsulinemia. These pathophysiological changes may impair oocyte quality, reduce embryo developmental competence, and negatively affect endometrial receptivity. In this context, combined supplementation with inositols and antioxidant compounds has been proposed as a strategy to modulate these pathways and potentially improve reproductive outcomes. This case series describes the clinical outcomes of four women without polycystic ovary syndrome (PCOS; recently proposed to be renamed polyendocrine metabolic syndrome) who had experienced previous assisted reproductive technology (ART) failure. Patients received supplementation for at least two months with Ovosicare® ProFIV, containing 1100 mg of myo-inositol and 300 mg of D-chiro-inositol in a 3.6:1 ratio, along with antioxidants, vitamins, minerals and probiotics before undergoing IVF-ICSI treatment. All cases resulted in successful pregnancies following supplementation and IVF-ICSI. Although limited by the small sample size and uncontrolled design, these preliminary observations suggest that preconception nutritional optimization with a multi-component supplement may represent a promising strategy to support reproductive outcomes in women with previous ART failure without PMOS. Prospective controlled studies are warranted to confirm these findings.
Keywords: In vitro fertilization, female infertility, myo-inositol, D-Chiro-inositol, 3.6:1 ratio, oocyte quality
Introduction
Infertility affects a significant proportion of reproductive-age women worldwide, and assisted reproduction techniques (ART) have become an essential tool in managing this condition. In vitro fertilization (IVF), often combined with intracytoplasmic sperm injection (ICSI), remains one of the most widely used ART methods, however, success rates vary considerably depending on age, ovarian reserve, oocyte quality, and other metabolic, hormonal and physiological factors. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age and is frequently associated with insulin resistance, a metabolic alteration that can impair ovarian function and compromise reproductive outcomes. Reflecting the growing recognition of the central role of metabolic dysfunction in this condition, the recently proposed term polyendocrine metabolic ovarian syndrome (PMOS) seeks to better capture its broader endocrine and metabolic dimensions, emphasizing metabolism as a key driver of reproductive disease rather than a minor feature. 1 Beyond PMOS, emerging evidence suggests that variations in insulin sensitivity and metabolic regulation may also negatively influence ovarian function, embryo quality, and pregnancy rates in women without a diagnosis of PMOS, supporting the concept that metabolic health may play an important role across the broader infertile population.2-6
Metabolic homeostasis plays a fundamental role in female reproductive physiology, influencing multiple processes from folliculogenesis to embryo implantation. Alterations in metabolic balance may impair key processes involved in follicular development, oocyte maturation, and embryo competence, thereby contributing to variability in ART outcomes. In addition, several clinical conditions and lifestyle factors, including PMOS, endometriosis, advanced maternal age, obesity, and unhealthy lifestyle, may influence reproductive potential through mechanisms such as oxidative stress, chronic inflammation, and altered metabolic signaling, which can impact oocyte competence and embryo development.7-9 Regarding endometrial receptivity, studies using donor oocyte and euploid embryo transfer models suggest that implantation potential is largely preserved in women of advanced maternal age and those with endometriosis, despite the presence of subtle molecular alterations in endometrial gene expression and signaling pathways that may influence implantation.10-12 By contrast, metabolic disorders such as PMOS and obesity, which are characterized by insulin resistance, chronic low-grade inflammation, and hormonal dysregulation, have been consistently associated with impaired endometrial function through alterations in gene expression, stromal decidualization, and signaling pathways essential for successful embryo implantation.13,14 Collectively, these findings support the hypothesis that optimizing metabolic homeostasis and oxidative balance before ART may be particularly relevant in women with previous ART failure, including those without a diagnosis of PMOS in whom subtle metabolic alterations may still be present. Considering these mechanisms, several natural nutritional supplements targeting metabolic signaling and oxidative balance have gained attention as potential supportive approaches in reproductive medicine, and when used as an adjunct to IVF-ICSI, may help mitigate these detrimental mechanisms, optimize the ovarian and endometrial environment, and ultimately improve reproductive outcomes.15,16
Building on this, Myo-inositol (MYO) and D-Chiro-inositol (DCI), two naturally occurring stereoisomers, act synergistically to regulate post-receptor insulin pathways, improving cellular glucose uptake and metabolic balance. 17 Beyond their role in insulin signaling, inositols are also involved in key intracellular pathways regulating follicle-stimulating hormone (FSH) signaling, oocyte maturation, and follicular development. 18 Supplementation with inositols is commonly performed using specific ratios of MYO and DCI to optimize their synergistic effects. Treatment with MYO and DCI in a specific ratio of 3.6:1 has been shown to improve reproductive outcomes more effectively than the 40:1 ratio.18,19 The main difference between these ratios lies in the amount of DCI, with the 3.6:1 combination providing 300 mg compared with 27.6 mg in the 40:1 formulation. DCI seems to play a key role in restoring ovarian function, which likely explains the observed differences in oocyte quality, pregnancy, and live-birth rates, as well as the reduced risk of ovarian hyperstimulation syndrome (OHSS).19,20 While the use of inositols is well supported in women with PMOS, it is plausible that women without PMOS, but with metabolic or oxidative factors as described above, may also benefit from their effects on oocyte competence and reproductive outcomes. Although there is not yet robust evidence from large randomized controlled trials in this population, exploratory studies and expert consensus suggest a potential physiological and clinical benefit that warrants further investigation. 21
In addition to inositols, some antioxidants such as vitamin E, D, B12, B6, B2, B1, zinc, selenium, melatonin, coenzyme Q10 (CoQ10) and Pomanox® (a standardized pomegranate extract with high antioxidant capacity) have been investigated for their potential role in supporting reproductive physiology.22,23 Oxidative stress has been suggested as one of the mechanisms that may negatively affect oocyte competence and embryo development, particularly in women undergoing IVF. Therefore, supplementation with antioxidants could be relevant in patients undergoing IVF since a well-known factor of physiological aging is the increased production of reactive oxygen species (ROS) in the ovary. 24 Although the biological rationale for metabolic and antioxidant supplementation is supported by experimental and clinical evidence, its potential role in women without PMOS undergoing ART remains insufficiently characterized. Accordingly, the aim of this case series is to describe four clinical cases of women without PMOS undergoing IVF-ICSI who received combined inositol and antioxidant supplementation as part of their preconception management, highlighting their clinical characteristics and outcomes.
Case Reports
Clinical characteristics of four women with previous ART failures who received a multi-component food supplement (Ovosicare® ProFIV, Procare Health SL, Spain) containing a specific 3.6:1 (MYO 1100 mg: DCI 300 mg) ratio, along with antioxidants (vitamin E, melatonin, CoQ10, Pomanox®), D and B-group vitamins (Quatrefolic®, vitamins B1, B2, B3, B6, B12), minerals (zinc, iodine, and selenium) and probiotics, administered as one sachet per day for at least two months prior to undergoing IVF are shown in Table 1. Written informed consent was obtained from all participants for the use and publication of their anonymized clinical data included in this case series.
Table 1.
Clinical characteristics of patients
| CHARACTERISTICS | CASE 1 | CASE 2 | CASE 3 | CASE 4 |
|---|---|---|---|---|
| Age | 36 | 40 | 29 | 33 |
| BMI (kg/m2) | N.A. | 19.2 | 27 | 22 |
| Obstetric history | G0 P0 | G0 P0 | G1 P0 | G0 P0 |
| PMOS diagnosis | No | No | No | No |
| Menstrual cycles | Regular | Regular (every 25d) | Regular (every 25d) | Regular (every 27d) |
| Relevant medical history | Undergone a tonsillectomy and uncomplicated urinary infections | Two laparoscopies for deep endometriosis with resection of lesions in the bladder and intestine | Familiar history of DM2, lipoma removal in adolescence and a voluntary termination of pregnancy at age 19 with a previous partner | None |
| Toxic habits | None | None | None | None |
| Infertility time (years) | N.A. | 5 | 6 months | 2 |
| AMH (ng/mL) | 3.0 | N.A. | 2.06 | 7.66 |
| TSH (IU/L) | N.A. | 2.69 | 2.6 | 1.06 |
| Vitamin D (ng/mL) | N.A. | 40.4 | 15.6 | 29 |
| Semen analysis | Asthenozoospermia (total motility: 10%) | Sperm DNA fragmentation (25%) and slight increase in chromosome 21 disomy | Normal | Normal |
| Treatments prior to supplementation | 2 failed IUI and 1 failed IVF cycle | 2 failed IVF cycles | 4 failed IVF cycles | 1 failed IVF cycle |
| Type of ART | IVF/ICSI | IVF/ICSI | IVF/ICSI | IVF/ICSI |
| Ovosicare® dosage | 1 sachet per day | 1 sachet per day | 1 sachet per day | 1 sachet per day |
| Time taking Ovosicare® | 3 mo | 3 mo | 6 mo | 2 mo |
AMH: Anti-Mullerian Hormone; ART: Assisted Reproductive Technique; BMI: Body Mass Index; DM2: Diabetes mellitus type 2; FSH: Follicle-Stimulating Hormone; G: gravidity; ICSI: Intracytoplasmic Sperm Injection; IUI: Intrauterine Insemination; IVF: in vitro fertilization; LH: Luteinizing Hormone; N.A.: not available; P: Parity; PMOS: Polyendocrine metabolic ovarian syndrome; TSH: Thyroid-Stimulating Hormone.
Clinical Case 1
A 36-year-old woman and her 45-year-old male partner presented to the fertility clinic at Hospital Vithas in Vigo, Spain, after several years of infertility and three prior unsuccessful ART at other centers, including two cycles of husband intrauterine insemination (H-IUI) and one cycle of IVF. The patient’s medical history was otherwise unremarkable, except for a history of uncomplicated urinary tract infections and a previous tonsillectomy. Assessment of ovarian reserve revealed an antral follicle count of 6 in the right ovary and 4 in the left ovary, with a serum anti-Müllerian hormone (AMH) level of 3.0 ng/mL. She was nulligravida and reported regular menstrual cycles. The male partner had chronic hepatitis C with an undetectable viral load and no prior offspring or other relevant medical conditions. Physical and gynecological examinations revealed no abnormalities. Semen analysis demonstrated asthenozoospermia, with total motility of 10%.
In a previous IVF cycle performed at an external center, 12 oocytes were retrieved following a combined recombinant FSH (rFSH) and human menopausal gonadotropin (hMG) stimulation protocol, of which 8 oocytes were successfully fertilized. Three embryos were transferred on day 3, but no pregnancy was achieved. A subsequent IVF cycle was initiated at our center using IVF-ICSI with the patient’s own oocytes, incorporating annexin columns to optimize fertilization rates. No pretreatment was administered prior to stimulation. A short GnRH antagonist protocol was employed, with daily administration of rFSH and recombinant luteinizing hormone (rLH) at a total dose of 262.5 IU for 9 days. Sixteen oocytes were retrieved, including 14 at metaphase II (MII), 1 at metaphase I (MI), and 1 at the germinal vesicle (GV) stage (Table 2). The mean oocyte quality score was 0.86. Qualitative assessment of oocyte quality was performed according to a scoring system based on ESHRE criteria, evaluating for each MII oocyte three prognostic parameters: uniform zona pellucida, homogeneous cytoplasm, and adequately sized polar body. Each parameter was assigned a value of 1 when present and 0 when absent. Signs associated with poor prognosis, including cytoplasmic inclusions in the perivitelline space, presence of vacuoles, and smooth endoplasmic reticulum aggregates, were recorded as negative findings. The sum of individual parameter scores generated an oocyte-specific quality score, and the mean score for each cycle was calculated as the average of all MII oocytes retrieved. Fertilization was achieved in 85.7% of injected MII oocytes (12/14), yielding three day-5 blastocysts from 12 fertilized oocytes. Embryo culture to day 5 resulted in 3 blastocysts (25% blastocyst rate), which were vitrified. All embryos generated were subsequently transferred, however, pregnancy was not achieved, and the patient was diagnosed with implantation failure according to current ESHRE criteria. 25
Table 2.
Comparative outcomes of IVF cycles without pretreatment versus cycles with pretreatment using Ovosicare® ProFIV.
| Parameter | First IVF cycle (Before supplementation with Ovosicare® ProFIV) | Second IVF cycle (After supplementation with Ovosicare® ProFIV) | ||
|---|---|---|---|---|
| Oocyte retrieval and maturation | ||||
| Trigger follicles ≥ 16 | 10 | 6 | ||
| Retrieved oocytes | 16 | 6 | ||
| Mature (MII) oocytes | 14 | 5 | ||
| Morphological assessment of MII oocytes | ||||
| | Normal | Abnormal | Normal | Abnormal |
| Uniform ZP | 10 | 4 | 4 | 1 |
| Uniform cytoplasm | 13 | 1 | 5 | 0 |
| Polar body of adequate size | 13 | 1 | 5 | 0 |
| Presence of inclusions in perivitelline space | 6 | 8 | 3 | 2 |
| Vacuolisation | 0 | 14 | 0 | 5 |
| SER aggregates | 0 | 14 | 0 | 5 |
| Embryological outcomes | ||||
| Fertilization | 12 | 2 | 4 | 1 |
| Cytoplasmatic halo | 7 | 7 | 3 | 2 |
| Early division | 14 | 0 | 5 | 0 |
| Blastocysts | 3 D5 BB | 11 | 2 D6 BB | 3 |
| PGT-A result | - | 1 euploid, 1 aneuploid | ||
| Summary outcomes | ||||
| Mean oocyte quality score | 0.86 | 0.9 | ||
| Fertilization rate | 85% | 80% | ||
| Fertilization score | 58.30% | 75% | ||
| Blastocyst rate | 25% | 50% | ||
| Embryo transferred after PGT-A | ND | 1BT | ||
| Clinical pregnancy | No | Yes | ||
BT: blastocyst transfer; D: day; IVF: in vitro fertilization; MII: metaphase II; ND: not determined; PGT-A: preimplantation genetic testing for aneuploidy; SER: smooth endoplasmic reticulum; ZP: zona pellucida.
For the subsequent IVF cycle, the patient initiated pretreatment with Ovosicare® ProFIV for 31 days prior to stimulation and continued for a total of three months. A short GnRH antagonist protocol was again employed using combined rFSH and rLH at 262.5 IU/day for 8 days, resulting in the retrieval of six oocytes (5 [MII] and 1 GV) (Table 2). In the IVF cycle without pre-treatment, the mean oocyte score was 0.86, whereas in the cycle with pre-treatment using Ovosicare® ProFIV, the mean score increased to 0.9. ICSI was performed using annexin columns, achieving a fertilization rate of 80% (4/5 MII oocytes). Among the resulting embryos, 75% exhibited favorable prognostic parameters, indicating a higher proportion of zygotes with favorable morphological characteristics (3/4), and culture in day 5 yielded two blastocysts from four fertilized oocytes (50% blastocyst rate) (Table 2). Both blastocysts were vitrified and subsequently analyzed by preimplantation genetic testing for aneuploidy (PGT-A), which identified one euploid and one aneuploid embryo. The euploid embryo was transferred in a modified natural cycle, resulting in a positive serum β-human corionic gonadotropin (β-hCG) level 11 days after embryo transfer, and subsequent ultrasound examination confirmed an ongoing intrauterine pregnancy.
Clinical Case 2
A 40-year-old woman and her 36-year-old male partner presented to Next Fertility Clinic in Valencia with a five-year history of primary infertility. The patient had a history of two laparoscopic surgeries for deep endometriosis with resection of foci in the bladder and bowel. She was nulligravid, reported regular menstrual cycles of 25 days, and experienced severe dysmenorrhea, with no history of contraceptive use. The male partner had undergone corrective surgery for unilateral epididymal stenosis and had normozoospermic semen parameters.
The couple had previously undergone two assisted reproductive treatments using their own gametes. The first treatment involved the transfer of three blastocysts on three separate occasions without achieving pregnancy. The second treatment included six cycles of ovarian stimulation for embryo accumulation with PGT-A. Three euploid blastocysts were obtained and transferred, resulting in no ongoing pregnancies: one transfer was negative, and two resulted in biochemical miscarriages. In total, six blastocyst transfers were performed, leading to two biochemical miscarriages.
Ultrasound revealed an anteverted uterus measuring 93 × 45 × 60 mm with signs of adenomyosis in the anterior wall. The endometrial lining was homogeneous, measuring 10 mm with a proliferative pattern. The right ovary measured 26 × 14 mm with four antral follicles, and the left ovary measured 20 × 12 mm with three antral follicles. Assessment of the patient’s thrombotic profile—including lupus anticoagulant, C-reactive protein, antinuclear antibodies (ANA), homocysteine, β2-glycoprotein I, and anti-cardiolipin antibodies—was within normal limits.
The initial diagnosis included diminished ovarian reserve, poor oocyte quality, and recurrent implantation failure. Given that ovarian factors were considered the primary limitation, a DuoStim protocol was implemented to maximize oocyte yield within a shortened timeframe and potentially improve oocyte and embryo quality. PGT-A was also recommended. The patient underwent pretreatment with Ovosicare® ProFIV for approximately 120 days prior to ovarian stimulation.
A detailed assessment of the male partner revealed borderline sperm DNA fragmentation (25%) and a slight increase in chromosome 21 disomy. Antioxidants and probiotics were prescribed to reduce sperm DNA fragmentation, and ICSI with sperm selection using microchips was planned. Concurrently, an endometrial receptivity test was performed after substituted cycle endometrial preparation, which indicated a pre-receptive endometrium, recommending embryo transfer after an additional day of progesterone supplementation.
The DuoStim protocol consisted of 150 IU FSH plus 150 IU hMG, with hypophyseal suppression using medroxyprogesterone 10 mg and ovulation induction with triptorelin 0.2 mg. During the first stimulation, three oocytes were retrieved, all MII, fertilized via ICSI, and developed into blastocysts (grade BB). In the second stimulation, seven oocytes were retrieved, six mature, and fertilized via ICSI, yielding two blastocysts (grades AB and BB). Trophectoderm biopsy was performed on five blastocysts, and PGT-A identified three euploid embryos. Table 3 summarizes the evolution of the three IVF cycles.
Table 3.
Comparative outcomes of IVF cycles without pretreatment (first and second cycles) versus the cycle with pretreatment using Ovosicare® ProFIV (third cycle).
| #Cycle | MII oocytes | Fertilization rate | Number of blastocytes (D5) | Euploid embryos | Euploidy rate | Transferred blastocytes | Evolutive pregnancy |
|---|---|---|---|---|---|---|---|
| 1 | - | - | 3 | - | - | 3 | No |
| 2 | 16 | 50% | 8 | 3 | 37.5% | 3 | No |
| 3 | 10 | 50% | 5 | 3 | 60% | 2 | Yes |
A double embryo transfer was performed, transferring the AB blastocyst from the second stimulation and the BB blastocyst from the first stimulation, timed according to the endometrial receptivity test. Fourteen days later, beta-hCG was 1986 mIU/mL, and subsequent ultrasound confirmed a dichorionic diamniotic twin pregnancy. At 33+4 weeks, a cesarean section was performed due to pre-eclampsia, resulting in the birth of two healthy boys.
Clinical case 3
A 29-year-old woman and her 32-year-old partner presented to Embriogyn Tarragona, Spain, after six months of attempting to conceive. The patient had an unremarkable medical history except for a lipoma removal in adolescence and a voluntary termination of pregnancy at age 19 with a previous partner. She reported regular, painless menstrual cycles every 25 days and had previously used hormonal contraceptives without complications. Her family history was notable for several cases of type II diabetes. The male partner had a history of intestinal perforation following a traffic accident eight years prior and a spontaneous pneumothorax, with a family history of pancreatic cancer in his maternal grandfather. Both partners denied toxic habits.
Primary fertility assessment revealed normal hormonal parameters, including FSH and LH within reference ranges, an AMH of 2.06 ng/mL, thyroid-stimulating hormone (TSH) of 2.6 mIU/mL, and a deficiency in vitamin D (15.6 ng/mL). Serologies for sexually transmitted infections were negative. Hysterosalpingography demonstrated bilateral tubal occlusion. Semen analysis revealed normozoospermia with a total motile sperm count of 34 million/mL. Peripheral karyotypes were normal in both partners. Physical examination at the clinic showed a BMI of 27, normal uterine and ovarian morphology, and an antral follicle count of 10 in the right ovary and 9 in the left.
The couple was diagnosed with primary infertility due to tubal factor and ovarian response concerns, and a series of IVF cycles with ovarian stimulation were initiated. The first antagonist protocol using rFSH 250 IU/day was cancelled due to a positive COVID-19 test. A second antagonist cycle with rFSH 300 IU/day resulted in retrieval of 7 oocytes, 5 of which were MII; 2 embryos reached blastocyst stage (Figure 1A) and were transferred, leading to a missed abortion at seven weeks. After evaluation, including an FSH receptor test suggesting high risk of low ovarian response, a third cycle with a long agonist protocol aimed at more synchronized follicular growth yielded 9 follicles but only one MII oocyte, which failed to produce a viable embryo (Figure 1B).
Figure 1.

Photos provided by the author. A: Embryos on day 3 of the second in vitro fertilization cycle. Both were transferred; they resulted in a pregnancy that ended in a missed abortion. B: Embryo from the third cycle, not suitable for transfer. C: Embryo generated in the fourth cycle of in vitro fertilization, not suitable for transfer. D: Embryo from the fifth cycle of in vitro fertilization, it was transferred and resulted in an ongoing pregnancy
A fourth IVF cycle, using high-dose hMG in monotherapy, resulted in the retrieval of four oocytes, of which only one was successfully fertilized, and no embryo transfer was possible due to poor embryo quality (Figure 1C). Subsequently, the couple implemented lifestyle modifications, including dietary optimization, regular exercise, and adjunctive antioxidant therapy with Ovosicare® ProFIV combined with resveratrol for six months. A repeat hysterosalpingography showed patent tubes, but spontaneous conception did not occur. In the final IVF attempt, an antagonist protocol with rFSH and hMG yielded 5 MII oocytes, 3 of which fertilized, resulting in 2 grade A embryos (Figure 1D) that were vitrified due to elevated TSH levels. After thyroid function normalization, one embryo was transferred, resulting in an ongoing pregnancy and the subsequent birth of a healthy female infant.
Clinical case 4
A couple attended the VIDA clinic in Seville after two years of primary infertility and a previous unsuccessful IVF attempt. The main indication for ART was the presence of an autosomal dominant hereditary disorder in the male partner: polycystic kidney disease (PKD). Both partners were 33 years old. The female patient had a BMI of 22.06 (height 1.55 m, weight 53 kg). Her medical history included hypothyroidism treated with levothyroxine (Eutirox® 25 mg/day) and an allergy to methimazole. Her AMH level was 7.66 ng/ml. Gynecological assessment revealed a normal anteflexed uterus, trilaminar endometrium of 6 mm in the follicular phase, and adequate ovarian reserve with 10 antral follicles in the right ovary and 12 in the left. Cervical cytology in 2021 was normal, and the embryo transfer test was easy.
The male partner had no known allergies and had been diagnosed with PKD in 2010 by ultrasound. He provided an external genetic report including sequencing of polycystic kidney disease 1 (PKD1) and PKD2 genes. Family history revealed that his father had undergone a renal transplant and was on immunosuppressive therapy, while his sister was also affected by PKD.
The couple previously underwent an ICSI cycle with preimplantation genetic testing for monogenic disorders (PGT-M) in an external clinic. Ovarian stimulation with gonadotropins yielded 22 oocytes, 17 of which were successfully fertilized, resulting in six blastocysts that were biopsied. Two embryos were confirmed to be free of the targeted monogenic disorder; however, euploidy status was not assessed. Two subsequent embryo transfers were performed: the first resulted in a negative pregnancy test, and the second led to a biochemical pregnancy.
At our clinic, the couple elected to undergo oocyte accumulation cycles to maximize the number of disease-free embryos and to allow assessment of embryo euploidy, reflecting their desire to have more than one child. The first stimulation cycle yielded 15 oocytes, of which 12 MII oocytes were vitrified. The second cycle yielded six oocytes, with three MII oocytes vitrified. Following these two cycles, the patient initiated treatment with Ovosicare® ProFIV.
The third cycle produced 15 oocytes, with 10 MII vitrified. The fourth stimulation cycle, after more than two months of supplementation, yielded 19 oocytes, 18 of which were in MII. These were microinjected fresh, resulting in 17 fertilizations and 9 blastocysts biopsied. Of these, 7 were euploid, 2 carried PKD, and 5 were transferable. Additionally, 25 previously vitrified oocytes were thawed and 24 MII were microinjected. Nineteen fertilized, and 8 blastocysts were biopsied. Six embryos were euploid, 4 were affected, and 2 were transferable. Overall, the couple obtained 7 transferable euploid embryos. The outcomes of the oocyte accumulation cycles, including the number of oocytes retrieved, MII oocytes vitrified, and subsequent fertilization results, are summarized in Table 4.
Table 4.
Comparative outcomes of IVF cycles without pretreatment (first and second cycles) versus the cycle with pretreatment using Ovosicare® ProFIV (third and fourth cycles)
| #Cycle | MII oocytes | Fertilization rate | Number of blastocytes (D5) | Euploid embryos | Euploidy rate | Evolutive pregnancy |
|---|---|---|---|---|---|---|
| 1-3 | 25 | 89% | 8 | 6 | 75% | No |
| 4 | 19 | 76% | 9 | 7 | 78% | Yes |
Discussion
Infertility remains a multifactorial challenge, even among couples with otherwise favorable prognostic factors. Across the four reported cases, patients exhibited varying degrees of poor oocyte quality, asynchronous follicular growth, low ovarian reserve and recurrent implantation failure. Notably, several patients exhibited risk factors associated with oxidative stress or metabolic imbalance despite the absence of PMOS. These included advanced maternal age (cases 1 and 2), endometriosis and adenomyosis (case 2), elevated BMI, vitamin D deficiency and familiar history of DM2 (case 3), elevated AMH levels (case 4), repeated ovarian stimulations (cases 2–4), and recurrent implantation failure (cases 1-3). The cumulative burden associated with all these factors may compromise oocyte competence, highlighting the potential importance of pre-treatment optimization strategies in this population.
Despite the heterogeneity of the underlying infertility factors, all four cases demonstrated improvements in oocyte competence, fertilization, and blastocyst development following pretreatment with Ovosicare® ProFIV, a multi-component formulation containing MYO (1100 mg) and DCI (300 mg) in a 3.6:1 ratio, combined with antioxidants, vitamins, minerals, and probiotics. After supplementation we observed higher mean oocyte quality scores (clinical case 1), increased proportion of embryos reaching the blastocyst stage (all cases), and, when PGT-A was applied, a higher number of euploid embryos available for transfer (clinical cases 2-4). Particularly in clinical case 1, despite a lower oocyte yield in the supplemented cycle, the proportion of embryos reaching the blastocyst stage increased and a euploid embryo was obtained, resulting in pregnancy. In Case 2, after repeated implantation failures and biochemical losses, supplementation preceded a DuoStim cycle with higher euploidy rates and a twin live birth. In Case 3, characterized by asynchronous follicular growth and poor embryo development, supplementation support was followed by improved embryo quality, resulting in pregnancy. In Case 4, following more than two months of supplementation, the IVF cycle yielded a higher proportion of MII oocytes, improved fertilization and blastocyst formation rates, and an increased number of euploid embryos, substantially enhancing the pool of transferable embryos in a PGT-M setting. Importantly, the observed improvements were not restricted to pregnancy achievement but involved several intermediate embryological endpoints—including oocyte competence, fertilization, blastocyst development, and euploid embryo yield—which followed a consistent direction across all cases. These observations were made in the context of largely comparable ovarian stimulation protocols across treatment cycles in most patients (Table 5). Although the multiple confounding factors inherent to ART preclude any causal inference, the temporal association between preconception supplementation and improvements in several embryological outcomes across four independent patients is noteworthy and provides a clinical pattern that warrants further investigation.
Table 5.
Comparative summary of stimulation regimens and trigger use in four clinical cases
| | | Before Ovosicare ProFIV ® | After Ovosicare ProFIV ® |
|---|---|---|---|
| Clinical case 1 | Cycle 1 | Antagonist protocol with rFSH and rLH (62.5 IU/day). | |
| Cycle 2 | | Antagonist protocol with rFSH and rLH (262.5 IU/day). | |
| Clinical case 2 | Cycle 1 | | rFSH (150 IU/day) and hMG-u (150 UI/day) |
| Clinical case 3 | Cycle 1 | Antagonist protocol with rFSH (250 IU/day). Cancelled on day 10 due to positive Covid-19 test. | |
| Cycle 2 | Antagonist protocol with rFSH (300 IU/day). Double trigger with agonist + hCG. | | |
| Cycle 3 | Agonist protocol with rFSH (300 IU/day) for 5 days, hMG for 3 days and hCG trigger | | |
| Cycle 4 | Antagonist protocol with hMG (337 IU/day) monotherapy for 9 days. Double trigger with GnRH agonist + hCG (6,500 IU) | | |
| Cycle 5 | | Antagonist protocol with rFSH (337 IU/day) and hMG. Triple trigger with GnRH agonist (3 doses of Decapeptyl, 9,750 µg total) + hCG (1,500 IU). | |
| Clinical case 4 | Cycle 1 | PPOS with rFSH (150 IU/day) and hMG (150 IU/day) for 9 days. Trigger with agonist (0.2 mg Decapeptyl). | |
| Cycle 2 | PPOS with rFSH (150 IU/day) and hMG (150 IU/day) for 9 days. Trigger with agonist. | | |
| Cycle 3 | | PPOS with folitropin delta (5.33 µg) and hMG (75 UI/day) for 9 days. Dual trigger with hCG (250 µg) + agonist (0.2mg Decapeptyl). | |
| Cycle 4 | | PPOS with folitropin delta (5.33 mcg) and hMG (75 UI/day) for 10 days. |
hMG: human menopausal gonadotropin; hCG: human chorionic gonadotropin; PPOS: progesterone-primed ovarian stimulation; rFSH: recombinant follicle-stimulating hormone; rLH: recombinant luteinizing hormone.
The biological rationale for metabolic and antioxidant optimization in reproductive medicine is supported by previous experimental and clinical evidence indicating that metabolic dysfunction, oxidative stress, and mitochondrial impairment may negatively affect oocyte competence, embryo development, and implantation potential, even in women without a formal diagnosis of PMOS. Advanced maternal age is one of the most important factors affecting female fertility, primarily through its impact on oocyte quality, mitochondrial function, and increased aneuploidy rates. 26 In addition, recent studies indicate that reduced insulin sensitivity negatively affects reproductive outcomes.2-6 Interestingly, these adverse effects may occur even before insulin resistance is fully established, in situations where insulin signaling is already partially impaired. Subclinical declines in insulin sensitivity, below diagnostic thresholds, have been shown to reduce pregnancy rates both in women with and without PMOS.6,27-29 It is noteworthy that reduced insulin sensitivity has been reported in 20% to 37% of women without PMOS and is often an underdiagnosed condition.2,30,31 When metabolic risk factors are present, such as overweight or obesity, a family history of diabetes, PMOS, hypertension, sedentarism or dyslipidemia, a comprehensive metabolic assessment and optimization of the patient’s metabolic profile prior to conception are strongly recommended. 32 This recommendation is supported by evidence that a partial impairment of insulin signaling may increase the risk of female infertility by promoting oxidative stress, disrupting energy metabolism, and impairing oocyte development, embryo quality, and implantation, ultimately leading to poorer reproductive outcomes. 33 In the present study, the patient in clinical case 3 presents with overweight and a family history of type 2 diabetes, while the patient in clinical case 4 shows elevated AMH levels suggestive of PMOS. These features may reflect an underlying metabolic risk profile in both cases, supporting the relevance of considering metabolic assessment and optimization in selected women undergoing ART, even in the absence of a formal diagnosis of PMOS.
In this context, the naturally compounds MYO and DCI represent promising interventions, as they enhance insulin signaling by acting as insulin second messengers, regulate glucose uptake, and modulate key intracellular pathways essential for oocyte maturation and embryo competence.18,34 The detailed mechanism of action of MYO and DCI under normal and insulin-resistant conditions has been extensively described elsewhere. 15 Briefly, MYO is converted into DCI by an insulin-dependent epimerase enzyme, with each isomer exerting distinct physiological roles. MYO predominates tissues with high metabolic demand, where it facilitates glucose uptake, whereas DCI is more abundant in glycogen-storing tissues, promoting glucose storage through glycogen synthesis and supports glucose oxidation for efficient energy production. In insulin-resistant women, epimerase activity is impaired, leading to reduced DCI availability and contributing to hyperglycemia. Indeed, in states of reduced insulin sensitivity, DCI levels have been reported to decrease by approximately 50% in plasma and up to 90% in insulin-sensitive tissues such as muscle, liver, and adipose tissue,35,36 underscoring the need for adequate DCI replenishment. The ovary, however, remains relatively insulin-sensitive, referred to as the “ovarian paradox”, where hyperinsulinemia overstimulates local DCI production at the expense of MYO, thereby promoting increased androgen synthesis and impairing oocyte quality. However, restoring ovarian homeostasis requires normalization of systemic insulin sensitivity as a primary step. Accordingly, supplementation with both inositol isomers may help re-establish the physiological MYO/DCI balance, improve insulin signaling, and ultimately support oocyte competence.37,38
Despite a significant amount of evidence suggesting that MYO and DCI metabolic derivatives act synergically, there is still ongoing debate concerning their optimal ratio. While the standard 40:1 supplementation ratio is designed to mimic the physiological MYO:DCI ratio observed in plasma, the 3.6:1 supplementation ratio aims to more closely reflect the endogenous balance found in both plasma and peripheral tissues, thereby supporting the restoration of metabolic and reproductive homeostasis. The 3.6:1 formulation mirrors the physiological availability of DCI derived from MYO under normal conditions. The kidneys produce approximately 4 g of MYO daily, of which 8–9% is converted to DCI via epimerase activity in peripheral tissues, yielding roughly 320–360 mg, closely aligning with the 300 mg provided by the 3.6:1 supplementation ratio. 36 The implications of these two ratios have been explored in randomized controlled trials. Mendoza et al. hypothesized that supplementation with higher doses of DCI could be advantageous for fertility, as it may compensate for the reduced endogenous DCI synthesis observed systemically and help restore ovarian homeostasis. In a double-blind, multicentre, randomized clinical trial including 60 women with PMOS undergoing ICSI, the effects of MYO and DCI supplementation at two different ratios (3.6:1 vs 40:1) were compared. 19 Pregnancy and live birth rates were significantly higher in the group receiving the 3.6:1 ratio compared to the 40:1 group (65.5% vs. 25.9% and 55.2% vs. 14.8%, respectively). In addition, the 3.6:1 ratio outperforms the ratio 40:1 in improving oocyte quality, underscoring the clinical advantage of the physiological 3.6:1 combination. 20
Additionally, MYO and DCI are not only recognized for their role in metabolic control but also possess antioxidant properties, complementing their effects on oocyte quality. Radical scavenging, metal chelation, and enzyme upregulation are the main mechanisms behind their antioxidant activity (Figure 2). As polyalcohol molecules, they can directly scavenge ROS, including superoxide and nitric oxide, reducing oxidative stress in a dose-dependent manner. Derivatives such as D-pinitol and DCI may also chelate Fe3+, preventing free radical formation in a mechanism similar to phytic acid.39,40 In addition, these inositols enhance endogenous antioxidant defenses by increasing the activity of enzymes such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase, glutathione reductase, and glutathione-S-transferase.41,42 Building on this, several antioxidants have been investigated as potential adjuvant strategies in reproductive medicine because of their capacity to modulate oxidative stress, inflammation, and mitochondrial function, all of which are relevant to oocyte competence and embryo development. Among these compounds, melatonin, CoQ10, and polyphenol-rich extracts have received increasing attention in the context of female infertility and ART. Endogenous production of CoQ10 and melatonin decreases with age, a phenomenon that has been proposed as one of several contributors to age-related reproductive decline.43,44 In the present series, several patients presented conditions previously associated with increased oxidative stress and mitochondrial dysfunction, including advanced reproductive age (cases 1 and 2), endometriosis (case 2), and metabolic risk factors (cases 3 and 4). ROS accumulate as mitochondrial function declines with age, leading to oxidative damage and reduced oocyte quality, while ROS overproduction in reproductive disorders such as endometriosis and metabolic dysfunction (e.g., insulin resistance, obesity) creates a pro-oxidative and inflammatory follicular environment that can impair folliculogenesis, spindle integrity, and subsequent embryo development. 45
Figure 2.

Molecular and cellular mechanisms involved in improving reproductive outcomes through nutritional supplementation. The diagram integrates the mechanisms of action of melatonin (via the MT1 receptor and the PI3K/Akt, FOXO3a, and Nrf2 pathways), CoQ10 (through the activation of PARKIN, PINK1, PGC-1α, and SIRT1, with effects on mitochondrial biogenesis and quality control via autophagy; and Nrf2 with effects on antioxidant enzymes), MYO and DCI (regulation of blood insulin and glucose), Pomanox® (inhibition of inflammation via NF-κB and reduction of IL-6, TNF-α, NO, PGE2, and IL-1β), and probiotics with vitamin D. Reducing oxidative stress is the central focus, with a positive impact on oocyte quality, maturation, follicular activation, ovarian aging, and embryonic development, resulting in an increased pregnancy rate. Some graphic elements (cell membrane, DNA, and mitochondria) were obtained from BioRender (biorender.com)
Melatonin, a major hormone produced by the pineal gland, plays a crucial role in female fertility by protecting ovarian function and enhancing reproductive outcomes. Within the ovarian follicle, melatonin shields granulosa cells and oocytes from oxidative stress, helping preserve their viability. As a potent endogenous antioxidant, melatonin activates the Nrf2 signaling pathway—a key regulator of oxidative homeostasis—upregulating antioxidant enzymes such as SOD and CAT, thereby reducing oxidative damage in ovarian cells, including oocytes (Figure 2).46-48 Beyond its antioxidant capacity, melatonin exhibits notable anti-aging properties within the ovarian microenvironment. It enhances mitochondrial function, promotes mitochondrial biogenesis, and modulates apoptotic pathways, contributing to the preservation of follicular reserve and delaying ovarian aging.49-51 The activation of molecular cascades such as PI3K–AKT–FOXO3 has been proposed in the regulation of follicular activation, further supporting the putative role of melatonin in maintaining ovarian longevity. 52 These biological effects may be particularly relevant in conditions associated with increased oxidative stress and mitochondrial dysfunction, including advanced reproductive age and endometriosis. In addition, melatonin also improves embryonic viability and developmental potential. Specifically, melatonin reduces oxidative stress and attenuates apoptosis by modulating the expression of apoptosis-related genes (e.g., decreasing p53 and Bax while increasing anti-apoptotic factors such as Bcl-2), thereby limiting follicular and embryonic cell death. 53 At the cellular level, melatonin improves cytoplasmic maturation by preserving mitochondrial function and promoting proper organelle distribution, including mitochondria, endoplasmic reticulum, and Golgi apparatus, which are essential for fertilization and early embryonic development. Preclinical studies in animal models suggest that melatonin can modulate early embryonic development primarily through its antioxidant and mitochondrial protective effects, while also interacting with growth-related signaling pathways such as IGF-1. 54 In addition, melatonin may contribute to embryo implantation by improving endometrial receptivity, partly through MT2 receptor–mediated signaling. 55 Clinical studies suggest that melatonin supplementation improves fertilization rates, oocyte quality, and embryo development, with increases in clinical pregnancy rates.56,57 Co-supplementation with MYO and melatonin has been reported to improve oocyte and embryo quality, increase blastocyst formation, and enhance implantation rates, even in patients with prior IVF failures.58-60 In the context of the present case series, which includes women with previous ART failures, this combined approach may have contributed to the observed improvements in reproductive outcomes. Also, melatonin supplementation appears to be particularly relevant in patients with endometriosis (clinical case 2), who exhibit reduced levels of melatonin and its metabolites, along with increased oxidative stress in the follicular microenvironment, contributing to infertility.61,62 In patients with endometriosis, melatonin has been shown to reduce oxidative and endoplasmic reticulum stress, limit cellular senescence, and improve mitochondrial function in granulosa cells. 61
Another relevant antioxidant is the CoQ10, a lipid-soluble mitochondrial cofactor that plays a critical role in female fertility by supporting oocyte quality and ovarian function. As a potent antioxidant, CoQ10 neutralizes free radicals and reduces oxidative stress damage in ovarian tissue, preserving cellular integrity and mitochondrial function. Oral supplementation with CoQ10 has been associated with improved reproductive outcomes, including clinical pregnancy and live birth rate in women undergoing ART procedures.63,64 Within the ovarian follicle, CoQ10 promotes oocyte maturation through the stabilization of the mitochondrial membrane potential and by increasing ATP generation in the respiratory chain 65 , while its antioxidant properties, mitochondrial support, promotion of autophagy, and inhibition of apoptosis help counteract age-related declines in oocyte quality. These biological effects of CoQ10 are mediated through key cellular signaling pathways, including PPAR, TNF, and MAPK, which regulate mitochondrial function, cellular metabolism, stress response, and apoptosis (Figure 2). 66 In vitro studies have shown that supplementation with CoQ10 increases the expression of Sirt1 in cumulus cells, a critical regulator of mitochondrial function and antioxidant defense. 67 Emerging evidence also suggests that CoQ10 may modulate redox signaling pathways involving Nrf2 and related antioxidant defense mechanisms, similar to melatonin, contributing to its ability to enhance cellular oxidative homeostasis. 68 During oocyte aging, proteins involved in mitochondrial biogenesis and energy production, specifically SIRT1 and PGC-1α, as well as those responsible for mitochondrial quality control through autophagy, namely PINK1 and PARKIN, show a marked decline. 69 Supplementation with CoQ10 has been demonstrated to prevent these age-related reductions, thereby preserving mitochondrial integrity, maintaining cellular energy levels, and protecting oocytes from apoptosis. All these mechanisms make CoQ10 particularly relevant for women with conditions associated with oxidative stress or metabolic dysfunction, including premature ovarian failure, PMOS, and pelvic inflammatory disease. In women with PMOS, CoQ10 has been shown to improve metabolic parameters, raising FSH, lowering testosterone levels, fasting blood sugar, reducing homeostasis model assessment of insulin resistance (HOMA-IR), and decreasing triglycerides, total cholesterol, and LDL cholesterol. 70 In patients with endometriosis, CoQ10 supplementation may enhance the in vitro maturation rate of immature oocytes, likely through its antioxidant properties and its role in improving mitochondrial function. 71 In this case series, CoQ10 is particularly beneficial for all patients, as each present one or more risk factors, including advanced maternal age, endometriosis, and metabolic dysfunction.
Finally, to complete the antioxidant complex in Ovosicare®, Pomanox® - a potent antioxidant derived from a patented pomegranate extract - has demonstrated beneficial effects on female fertility, primarily through its antioxidant, anti-inflammatory, and anti-diabetic properties, among other mechanisms.22,72 It is composed of several bioactive constituents, including phenolic compounds such as ellagitannins (notably punicalagins), ellagic acid derivatives, and flavonoids, as well as the polyunsaturated fatty acid punicic acid. Approximately 100 different ellagitannins have been identified in pomegranate fruit and plant tissues, with punicalagins, punicalin A, and punicalin B being the most abundant and largely responsible for its in vitro antioxidant activity. 72 Regarding its antioxidant profile, pomegranate has been shown to reduce ROS levels and upregulate antioxidant enzyme activity. 73 These effects are mediated, at least in part, through the inhibition of nuclear factor-κB (NF-κB) and the activation of PPARs (Figure 2).74,75 In vitro, P. granatum extracts reduce key inflammatory mediators, including NO, PGE2, IL-1β, IL-6, and TNF-α (NO, PGE2, IL-1β, IL-6, TNF-α). 76 In vivo, pomegranate juice and punicalagin decrease inflammatory markers, neutrophil infiltration, and NF-κB expression, while enhancing antioxidant defenses, thereby protecting against tissue damage. 77 Clinically, pomegranate extracts and pomegranate juice have been shown to lower fasting blood glucose, improve glucose transporter type 4 (GLUT-4) expression, similar to the effects of MYO, reduce insulin resistance, and support β-cell function in patients with type 2 diabetes.78,79 Moreover, in women with PMOS, pomegranate consumption has demonstrated metabolic, hormonal, oxidative, and anti-inflammatory benefits, improving cardiovascular and reproductive health outcomes.80,81
Furthermore, beyond its antioxidant components, vitamin D and probiotics may provide additional benefits for reproductive regulation and endometrial receptivity. Observational studies suggest that insufficient vitamin D levels can impair reproductive function by affecting steroid hormone regulation, follicular development, and endometrial receptivity, as the vitamin D receptor is expressed in the ovaries, endometrium, and placental tissue. In addition to these direct effects on reproduction, vitamin D deficiency is frequently associated with metabolic and autoimmune disorders that may further contribute to infertility.82,83 Insulin resistance, which has been linked to Vitamin D deficiency, is known to impair ovulatory function and endometrial receptivity. 84 Vitamin D also plays a critical role in glucose metabolism and insulin sensitivity, suggesting that its deficiency could exacerbate insulin resistance and, consequently, worsen fertility-related outcomes.85,86 It may further improve insulin action by upregulating the expression of insulin receptors, thereby enhancing insulin-mediated glucose transport. 87 In addition, observational studies and RCTs suggest that vitamin D supplementation may improve fertility by reducing inflammatory markers and enhancing endometrial receptivity, potentially increasing implantation and pregnancy rates.83,88 The patient from clinical case number 3 had a vitamin D deficiency, apart from a family history of type 2 diabetes. This patient had previously undergone three unsuccessful IVF cycles, suggesting that underlying metabolic and microbiological factors may have been contributing to implantation failure beyond the scope of standard assisted reproduction protocols. Furthermore, emerging evidence shows that the supplementation of probiotics may also contribute to improving receptivity by promoting favorable vaginal and endometrial microbiota, restoring Lactobacillus dominance and reducing the abundance of potentially pathogenic bacterial species. 89 In fact, one recent randomized clinical trial (n=112) evaluated the effect of vaginal probiotics, vitamin D supplementation, and their combination in women with recurrent implantation failure, finding that combined therapy achieved the highest pregnancy rate (46.4%) — significantly superior to probiotics alone (14.2%), vitamin D alone (17.8%), and standard IVF treatment (10.7%) — alongside significant reductions in Th1/Th2 ratio and NK cell activity, suggesting a synergistic immunomodulatory mechanism. 90
Case reports are inherently hypothesis-generating and subject to selection bias; therefore, no causal relationship can be established. In the present series, all patients underwent additional interventions that may have independently influenced reproductive outcomes, including modifications to ovarian stimulation protocols, the use of PGT-A (all cases) or PGT-M (case 4), sperm selection techniques (case 2), endometrial receptivity testing, optimization of thyroid function (case 4), and the natural inter-cycle variability of ART outcomes. Furthermore, potential differences in laboratory performance or clinical management between treatment cycles cannot be excluded. The absence of standardized metabolic and oxidative stress biomarkers (e.g., HOMA-IR, fasting insulin, or oxidative stress markers) further limits mechanistic interpretation. Nevertheless, the consistent observation of improved embryo developmental competence and successful pregnancies across four women with previous ART failure, together with the within-patient comparison between previous unsuccessful cycles and the supplemented cycle, provides a clinical signal supporting the hypothesis that preconception metabolic optimization may be relevant beyond women with PMOS. Although these findings are encouraging, they should be interpreted as exploratory observations rather than evidence of efficacy.
Importantly, while the biological rationale supporting the individual components of the investigated formulation is based on previously published experimental and clinical evidence, the present case series neither demonstrates that these mechanisms were responsible for the observed outcomes nor allows attribution of the clinical findings to any individual ingredient or to the formulation itself. Rather, the mechanistic discussion is intended to place clinical observations within the context of the current biological understanding of metabolic optimization and oxidative stress in reproductive medicine, thereby providing biological plausibility for the observed clinical pattern rather than evidence of causality. Consequently, these observations should be regarded as hypothesis-generating and as an additional contribution to the growing body of evidence supporting further investigation of metabolic optimization strategies in reproductive medicine, rather than as a basis for recommending a specific formulation in clinical practice.
Conclusion
This case series highlights the rationale for a comprehensive supplementation strategy in women undergoing ART. Because metabolic, oxidative, inflammatory, and microbiome-related factors are highly interconnected, isolating the contribution of each individual pathway is often challenging. A multi-component formulation designed to target several of these mechanisms simultaneously may therefore represent a biologically plausible approach to addressing the complex factors influencing female fertility and IVF outcomes. The present case series provides preliminary, hypothesis-generating clinical evidence suggesting that supplementation with a 3.6:1 MYO (1100 mg):DCI (300 mg) ratio combined with antioxidants, vitamins, minerals, and probiotics may be associated with improved oocyte competence, embryo development, and pregnancy outcomes in selected women without PMOS undergoing IVF–ICSI following prior ART failures. Although confirmatory studies in larger controlled cohorts are warranted, strategies aimed at optimizing metabolic function and mitochondrial health may represent a promising adjunct in contemporary reproductive medicine. Future adequately powered randomized controlled trials will be essential to determine the clinical benefit of this approach, identify the patient populations most likely to benefit, and clarify the contribution of multi-component nutritional interventions beyond their biological plausibility.
Footnotes
Author Contributions: All authors contributed equally to the work.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
ORCID iD
LI Devesa Otero https://orcid.org/0009-0005-7866-8128
Ethical Considerations
The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was not required for this case series.
Consent to Participate
Written informed consent was obtained from all participants for the use and publication of their anonymized clinical data included in this case series.
References
- 1.Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339. doi: 10.1016/S0140-6736(26)00717-8. [DOI] [PubMed] [Google Scholar]
- 2.Albert AB, Corachán A, Juárez-Barber E, et al. Association of insulin resistance with in vitro fertilization outcomes in women without polycystic ovarian syndrome: potential improvement with metformin treatment. Hum Reprod. 2025;40(8):1562-1569. doi: 10.1093/humrep/deaf100. [DOI] [PubMed] [Google Scholar]
- 3.Wang H, Zhang Y, Fang X, Kwak-Kim J, Wu L. Insulin resistance adversely affect IVF outcomes in lean women without PCOS. Front Endocrinol (Lausanne). 2021;12:734638. doi: 10.3389/fendo.2021.734638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zhang R, Wang X, Mo M, Liu Z, Liu S. Insulin resistance as a determinant of fertilization efficiency in polycystic ovary syndrome patients undergoing IVF/ICSI: a retrospective cohort study. Reprod Biol Endocrinol. 2025;23(1):120. doi: 10.1186/s12958-025-01453-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Li F, Qi J, Li L, Yan TF. Impact of insulin resistance on IVF/ICSI outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2024;299:54-61. doi: 10.1016/j.ejogrb.2024.05.042. [DOI] [PubMed] [Google Scholar]
- 6.Peng L, Yang W, Du M, et al. Metformin improves pregnancy outcomes in non-PCOS women with insulin resistance and recurrent implantation failure before frozen embryo transfer. Front Endocrinol (Lausanne). 2025;16:1671899. doi: 10.3389/fendo.2025.1671899. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Huang XD, Sun ZY, Yu Q. Impact of endometriosis on embryo quality and endometrial receptivity in women undergoing assisted reproductive technology. Reprod Biol. 2023;23(2):100733. doi: 10.1016/j.repbio.2023.100733. [DOI] [PubMed] [Google Scholar]
- 8.Cimadomo D, Fabozzi G, Vaiarelli A, Ubaldi N, Ubaldi FM, Rienzi L. Impact of maternal age on oocyte and embryo competence. Front Endocrinol (Lausanne). 2018;9:327. doi: 10.3389/fendo.2018.00327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Morimoto A, Rose RD, Smith KM, et al. Granulosa cell metabolism at ovulation correlates with oocyte competence and is disrupted by obesity and aging. Hum Reprod. 2024;39(9):2053-2066. doi: 10.1093/humrep/deae154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Miravet-Valenciano J, Ruiz-Alonso M, Gómez E, Garcia-Velasco JA. Endometrial receptivity in eutopic endometrium in patients with endometriosis: it is not affected, and let me show you why. Fertil Steril. 2017;108(1):28-31. doi: 10.1016/j.fertnstert.2017.06.002. [DOI] [PubMed] [Google Scholar]
- 11.Pirtea P, De Ziegler D, Ayoubi JM. Endometrial receptivity in adenomyosis and/or endometriosis. Fertil Steril. 2023;119(5):741-745. doi: 10.1016/j.fertnstert.2023.03.004. [DOI] [PubMed] [Google Scholar]
- 12.Schwartz KM, Yilmaz BD, Chan M, Cedars MI, Cakmak H, Huang D. Endometrial aging and uterine receptivity: endometrial receptivity analysis (ERA) outcomes in female patients of diverse age groups. J Assist Reprod Genet. 2026;43:1169-1177. doi: 10.1007/s10815-026-03824-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Schulte MMB, Tsai JH, Moley KH. Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation. Reprod Sci. 2015;22(1):6-14. doi: 10.1177/1933719114561552. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021;27(3):584-618. doi: 10.1093/humupd/dmaa051. [DOI] [PubMed] [Google Scholar]
- 15.Armijo-Sánchez A, Benítez Castillo N, García-Vidal E, et al. Treatment with a patented 3.6:1 myo-inositol to D-chiro-inositol ratio, antioxidants, vitamins and minerals food supplement in women with a history of assisted reproductive technique (ART) failures: a series of case reports. Clin Med Insights Case Rep. 2024;17:11795476241242265. doi: 10.1177/11795476241242265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Jorge IS, Clara LB, Bibiana RJ, Silvia TA. Can a specific 3.6:1 myoinositol (1100 mg) to D-chiro-inositol (300 mg) ratio-based food supplement increase pregnancy rates in advanced age conception? A series of case reports. Obstet Gynecol Cases Rev. 2023;10(1):233. doi: 10.23937/2377-9004/1410233 [DOI] [Google Scholar]
- 17.Genazzani AD, Genazzani AR. Polycystic ovary syndrome as metabolic disease: new insights on insulin resistance. Eur Endocrinol. 2023;19(1):71. doi: 10.17925/EE.2023.19.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Gambioli R, Forte G, Buzzaccarini G, Unfer V, Laganà AS. Myo-inositol as a key supporter of fertility and physiological gestation. Pharmaceuticals (Basel). 2021;14(6):504. doi: 10.3390/ph14060504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mendoza N, Diaz-Ropero MP, Aragon M, et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;35(8):695-700. doi: 10.1080/09513590.2019.1576620. [DOI] [PubMed] [Google Scholar]
- 20.Mendoza N, Galan MI, Molina C, et al. High dose of D-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2020;36(5):398-401. doi: 10.1080/09513590.2019.1681959. [DOI] [PubMed] [Google Scholar]
- 21.Wdowiak A, Bakalczuk S, Filip M, Laganà AS, Unfer V. The clinical use of myo-inositol in IVF-ET: a position statement from the Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), the Polish Society of Andrology, and the International Scientific Association for the Support and Development of Medical Technologies. J Clin Med. 2025;14(2):558. doi: 10.3390/jcm14020558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Vašková J, Klepcová Z, Špaková I, et al. The importance of natural antioxidants in female reproduction. Antioxidants (Basel). 2023;12(4):907. doi: 10.3390/antiox12040907. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Rodríguez-Varela C, Labarta E. Clinical application of antioxidants to improve human oocyte mitochondrial function: a review. Antioxidants (Basel). 2020;9(12):1197. doi: 10.3390/antiox9121197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Homer HA. The role of oocyte quality in explaining “unexplained” infertility. Semin Reprod Med. 2020;38(1):21-28. doi: 10.1055/s-0040-1721377. [DOI] [PubMed] [Google Scholar]
- 25.ESHRE Working Group on Recurrent Implantation Failure. Cimadomo D, De Los Santos MJ, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. doi: 10.1093/hropen/hoad023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Farquhar CM, Bhattacharya S, Repping S, et al. Female subfertility. Nat Rev Dis Primers. 2019;5(1):7. doi: 10.1038/s41572-018-0058-8. [DOI] [PubMed] [Google Scholar]
- 27.Song H, Yu Z, Li P, Wang Y, Shi Y. HOMA-IR for predicting clinical pregnancy rate during IVF. Gynecol Endocrinol. 2022;38(1):33-38. doi: 10.1080/09513590.2021.1952976. [DOI] [PubMed] [Google Scholar]
- 28.Li Y, Jiang Y, Zhang S, Liu H, Zhang C. Association of HOMA-IR with ovarian sensitivity index in women undergoing IVF/ICSI: a retrospective cohort study. Diabetes Metab Syndr Obes. 2023;16:309-320. doi: 10.2147/DMSO.S399105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wu S, Wu Y, Fang L, Lu X. Association of insulin resistance surrogates with live birth outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization. BMC Pregnancy Childbirth. 2025;25(1):25. doi: 10.1186/s12884-024-07131-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Karnatak R, Agarwal A, Asnani M, Singh R. The effect of insulin resistance on ovulation induction with clomiphene citrate in non-polycystic ovary syndrome (PCOS) women. Cureus. 2022;14:e27433. doi: 10.7759/cureus.27433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wang X, Cai S, Tang S, et al. Effect of lifestyle or metformin interventions before IVF/ICSI treatment on infertile women with overweight/obese and insulin resistance: a factorial design randomised controlled pilot trial. Pilot Feasibility Stud. 2023;9(1):160. doi: 10.1186/s40814-023-01388-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.American Diabetes Association . 3. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S34-S39. doi: 10.2337/dc21-S003. [DOI] [PubMed] [Google Scholar]
- 33.Lei R, Chen S, Li W. Advances in the study of the correlation between insulin resistance and infertility. Front Endocrinol (Lausanne). 2024;15:1288326. doi: 10.3389/fendo.2024.1288326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Bizzarri M, Monti N, Piombarolo A, Angeloni A, Verna R. Myo-inositol and D-chiro-inositol as modulators of ovary steroidogenesis: a narrative review. Nutrients. 2023;15(8):1875. doi: 10.3390/nu15081875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006;29(2):300-305. doi: 10.2337/diacare.29.02.06.dc05-1070. [DOI] [PubMed] [Google Scholar]
- 36.Larner J. D-chiro-inositol: its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47-60. doi: 10.1080/15604280212528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021;18(1):171. doi: 10.1186/s12978-021-01207-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288(6):1405-1411. doi: 10.1007/s00404-013-2855-3. [DOI] [PubMed] [Google Scholar]
- 39.Graf E, Eaton JW. Antioxidant functions of phytic acid. Free Radic Biol Med. 1990;8(1):61-69. doi: 10.1016/0891-5849(90)90146-A. [DOI] [PubMed] [Google Scholar]
- 40.Graf E, Empson KL, Eaton JW. Phytic acid. A natural antioxidant. J Biol Chem. 1987;262(24):11647-11650. doi: 10.1016/S0021-9258(18)60858-0. [DOI] [PubMed] [Google Scholar]
- 41.Vasaikar N, Mahajan U, Patil KR, et al. D-pinitol attenuates cisplatin-induced nephrotoxicity in rats: impact on pro-inflammatory cytokines. Chem Biol Interact. 2018;290:6-11. doi: 10.1016/j.cbi.2018.05.003. [DOI] [PubMed] [Google Scholar]
- 42.Rengarajan T, Rajendran P, Nandakumar N, Balasubramanian MP, Nishigaki I. Free radical scavenging and antioxidant activity of D-pinitol against 7,12-dimethylbenz(a)anthracene-induced breast cancer in Sprague-Dawley rats. Asian Pac J Trop Dis. 2014;4(5):384-390. doi: 10.1016/S2222-1808(14)60592-2. [DOI] [Google Scholar]
- 43.Reiter RJ, Sharma R, Romero A, et al. Aging-related ovarian failure and infertility: melatonin to the rescue. Antioxidants (Basel). 2023;12(3):695. doi: 10.3390/antiox12030695. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev. 2007;65(6):286-293. doi: 10.1111/j.1753-4887.2007.tb00306.x. [DOI] [PubMed] [Google Scholar]
- 45.Yan F, Zhao Q, Li Y, et al. The role of oxidative stress in ovarian aging: a review. J Ovarian Res. 2022;15(1):100. doi: 10.1186/s13048-022-01032-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Kim EH, Kim GA, Taweechaipaisankul A, et al. Melatonin enhances porcine embryo development via the Nrf2/ARE signaling pathway. J Mol Endocrinol. 2019;63(3):175-185. doi: 10.1530/JME-19-0093. [DOI] [PubMed] [Google Scholar]
- 47.Zhang K, Guo J, Wang S, et al. Melatonin protects bovine oocyte from βHB-induced oxidative stress through the Nrf2 pathway. Theriogenology. 2025;234:64-72. doi: 10.1016/j.theriogenology.2024.11.025. [DOI] [PubMed] [Google Scholar]
- 48.Ghantabpour T, Goudarzi N, Parsaei H. Overview of Nrf2 as a target in ovary and ovarian dysfunctions focusing on its antioxidant properties. J Ovarian Res. 2025;18(1):60. doi: 10.1186/s13048-025-01639-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Niu Y, Zhou W, Nie Z, Shin K, Cui X. Melatonin enhances mitochondrial biogenesis and protects against rotenone-induced mitochondrial deficiency in early porcine embryos. J Pineal Res. 2020;68(2):e12627. doi: 10.1111/jpi.12627. [DOI] [PubMed] [Google Scholar]
- 50.Zheng B, Meng J, Zhu Y, Ding M, Zhang Y, Zhou J. Melatonin enhances SIRT1 to ameliorate mitochondrial membrane damage by activating PDK1/Akt in granulosa cells of PCOS. J Ovarian Res. 2021;14(1):152. doi: 10.1186/s13048-021-00912-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Tao JL, Zhang X, Zhou JQ, et al. Melatonin alleviates hypoxia-induced apoptosis of granulosa cells by reducing ROS and activating MTNR1B–PKA–caspase8/9 pathway. Antioxidants (Basel). 2021;10(2):184. doi: 10.3390/antiox10020184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Yang C, Liu Q, Chen Y, et al. Melatonin delays ovarian aging in mice by slowing down the exhaustion of ovarian reserve. Commun Biol. 2021;4(1):534. doi: 10.1038/s42003-021-02042-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Yang L, Wang Q, Cui M, Li Q, Mu S, Zhao Z. Effect of melatonin on the in vitro maturation of porcine oocytes, development of parthenogenetically activated embryos, and expression of genes related to the oocyte developmental capability. Animals (Basel). 2020;10(2):209. doi: 10.3390/ani10020209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Wang P, Sun Y, Li Y, et al. Monochromatic green light stimulation during incubation shortened the hatching time via pineal function in White Leghorn eggs. J Anim Sci Biotechnol. 2021;12(1):17. doi: 10.1186/s40104-020-00539-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Novinbahador T, Abroon S, Motlagh K, Nouri M. The influence of maternal melatonin on embryo implantation: a crucial factor in reproductive outcomes. Birth Defects Res. 2026;118(2):e70021. doi: 10.1002/bdr2.70021. [DOI] [PubMed] [Google Scholar]
- 56.Wu Y, Huang W, Tang L, et al. Melatonin improved the outcomes of women with ART: a systematic review and meta-analysis of randomized trials. Front Reprod Health. 2025;7:1680984. doi: 10.3389/frph.2025.1680984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Hu KL, Ye X, Wang S, Zhang D. Melatonin application in assisted reproductive technology: a systematic review and meta-analysis of randomized trials. Front Endocrinol (Lausanne). 2020;11:160. doi: 10.3389/fendo.2020.00160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Unfer V, Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol. 2011;27(11):857-861. doi: 10.3109/09513590.2011.564687. [DOI] [PubMed] [Google Scholar]
- 59.Carlomagno G, Nordio M, Chiu TT, Unfer V. Contribution of myo-inositol and melatonin to human reproduction. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):267-272. doi: 10.1016/j.ejogrb.2011.07.038. [DOI] [PubMed] [Google Scholar]
- 60.Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles: a prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010;14(6):555-561. [PubMed] [Google Scholar]
- 61.Lin X, Dai Y, Tong X, et al. Excessive oxidative stress in cumulus granulosa cells induced cell senescence contributes to endometriosis-associated infertility. Redox Biol. 2020;30:101431. doi: 10.1016/j.redox.2020.101431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Hsu PY, Chou PY, Cheng YM, et al. Relationship between urinary 6-sulfatoxymelatonin excretion and cancer antigen 125 in women with endometriosis. Gynecol Minim Invasive Ther. 2014;3(4):105-108. doi: 10.1016/j.gmit.2014.12.005. [DOI] [Google Scholar]
- 63.Zhu F, Yin S, Yang B, et al. TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2023;21(1):64. doi: 10.1186/s12958-023-01119-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Florou P, Anagnostis P, Theocharis P, Chourdakis M, Goulis DG. Does coenzyme Q10 supplementation improve fertility outcomes in women undergoing assisted reproductive technology procedures? A systematic review and meta-analysis of randomized-controlled trials. J Assist Reprod Genet. 2020;37(10):2377-2387. doi: 10.1007/s10815-020-01906-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Bozdemir N, Cakir C, Topcu U, Uysal F. A comprehensive review of mitochondrial complex I during mammalian oocyte maturation. Genesis. 2025;63(3):e70017. doi: 10.1002/dvg.70017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Yang L, Wang H, Song S, et al. Systematic understanding of anti-aging effect of coenzyme Q10 on oocyte through a network pharmacology approach. Front Endocrinol (Lausanne). 2022;13:813772. doi: 10.3389/fendo.2022.813772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Lee CH, Kang MK, Sohn DH, Kim HM, Yang J, Han SJ. Coenzyme Q10 ameliorates the quality of mouse oocytes during in vitro culture. Zygote. 2022;30(2):249-257. doi: 10.1017/S0967199421000617. [DOI] [PubMed] [Google Scholar]
- 68.Mantle D. Coenzyme Q10 and intracellular signalling pathways: clinical relevance. Int J Mol Sci. 2025;26(22):11024. doi: 10.3390/ijms262211024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Niu YJ, Zhou W, Nie ZW, et al. Ubiquinol-10 delays postovulatory oocyte aging by improving mitochondrial renewal in pigs. Aging (Albany NY). 2020;12(2):1256-1271. doi: 10.18632/aging.102681. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Izadi A, Ebrahimi S, Shirzai S, et al. Hormonal and metabolic effects of coenzyme Q10 and/or vitamin E in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2018. doi: 10.1210/jc.2018-01221. [DOI] [PubMed] [Google Scholar]
- 71.Dymanowska-Dyjak I, Frankowska K, Abramiuk M, Polak G. Oxidative imbalance in endometriosis-related infertility—the therapeutic role of antioxidants. Int J Mol Sci. 2024;25(12):6298. doi: 10.3390/ijms25126298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Benedetti G, Zabini F, Tagliavento L, Meneguzzo F, Calderone V, Testai L. An overview of the health benefits, extraction methods and improving the properties of pomegranate. Antioxidants (Basel). 2023;12(7):1351. doi: 10.3390/antiox12071351. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Lorzadeh E, Heidary Z, Mohammadi M, Nadjarzadeh A, Ramezani-Jolfaie N, Salehi-Abargouei A. Does pomegranate consumption improve oxidative stress? A systematic review and meta-analysis of randomized controlled clinical trials. Clin Nutr ESPEN. 2022;47:117-127. doi: 10.1016/j.clnesp.2021.11.017. [DOI] [PubMed] [Google Scholar]
- 74.Katz SR, Newman RA, Lansky EP. Punica granatum: heuristic treatment for diabetes mellitus. J Med Food. 2007;10(2):213-217. doi: 10.1089/jmf.2006.290. [DOI] [PubMed] [Google Scholar]
- 75.Feng X, Yang Q, Wang C, Tong W, Xu W. Punicalagin exerts protective effects against ankylosing spondylitis by regulating NF-κB-TH17/JAK2/STAT3 signaling and oxidative stress. Biomed Res Int. 2020;2020:4918239. doi: 10.1155/2020/4918239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Xu J, Zhao Y, Aisa HA. Anti-inflammatory effect of pomegranate flower in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. Pharm Biol. 2017;55(1):2095-2101. doi: 10.1080/13880209.2017.1357737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Shah TA, Parikh M, Patel KV, Joshi CG, Gandhi TR. Evaluation of the effect of Punica granatum juice and punicalagin on NFκB modulation in inflammatory bowel disease. Mol Cell Biochem. 2016;419(1-2):65-74. doi: 10.1007/s11010-016-2750-x. [DOI] [PubMed] [Google Scholar]
- 78.Khajebishak Y, Payahoo L, Alivand M, et al. Effect of pomegranate seed oil supplementation on the GLUT-4 gene expression and glycemic control in obese people with type 2 diabetes: a randomized controlled clinical trial. J Cell Physiol. 2019;234(11):19621-19628. doi: 10.1002/jcp.28561. [DOI] [PubMed] [Google Scholar]
- 79.Banihani SA, Makahleh SM, El-Akawi Z, et al. Fresh pomegranate juice ameliorates insulin resistance, enhances β-cell function, and decreases fasting serum glucose in type 2 diabetic patients. Nutr Res. 2014;34(10):862-867. doi: 10.1016/j.nutres.2014.08.003. [DOI] [PubMed] [Google Scholar]
- 80.Al-Dujaili EAS, Casey C, Stockton A. Antioxidant properties and beneficial cardiovascular effects of a natural extract of pomegranate in healthy volunteers: a randomized preliminary single-blind controlled study. Antioxidants (Basel). 2022;11(11):2124. doi: 10.3390/antiox11112124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Abedini M, Ghasemi-Tehrani H, Tarrahi MJ, Amani R. The effect of concentrated pomegranate juice consumption on risk factors of cardiovascular diseases in women with polycystic ovary syndrome: a randomized controlled trial. Phytother Res. 2021;35(1):442-451. doi: 10.1002/ptr.6820. [DOI] [PubMed] [Google Scholar]
- 82.Lerchbaum E, Obermayer-Pietsch B. Mechanisms in endocrinology: vitamin D and fertility: a systematic review. Eur J Endocrinol. 2012;166(5):765-778. doi: 10.1530/EJE-11-0984. [DOI] [PubMed] [Google Scholar]
- 83.Mousa A, Abell S, Scragg R, Courten B. Vitamin D in reproductive health and pregnancy. Semin Reprod Med. 2016;34(2):e1-e13. doi: 10.1055/s-0036-1583529. [DOI] [PubMed] [Google Scholar]
- 84.Tai K, Need AG, Horowitz M, Chapman IM. Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition. 2008;24(3):279-285. doi: 10.1016/j.nut.2007.11.006. [DOI] [PubMed] [Google Scholar]
- 85.Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;77(3):343-350. doi: 10.1111/j.1365-2265.2012.04434.x. [DOI] [PubMed] [Google Scholar]
- 86.Mohan A, Haider R, Fakhor H, et al. Vitamin D and polycystic ovary syndrome (PCOS): a review. Ann Med Surg (Lond). 2023;85(7):3506-3511. doi: 10.1097/MS9.0000000000000879. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017-2029. doi: 10.1210/jc.2007-0298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Chu J, Gallos I, Tobias A, Tan B, Eapen A, Coomarasamy A. Vitamin D and assisted reproductive treatment outcome: a systematic review and meta-analysis. Hum Reprod. 2018;33(1):65-80. doi: 10.1093/humrep/dex326. [DOI] [PubMed] [Google Scholar]
- 89.Filardo S, Di Pietro M, Mastromarino P, Porpora MG, Sessa R. A multi-strain oral probiotic improves the balance of the vaginal microbiota in women with asymptomatic bacterial vaginosis: preliminary evidence. Nutrients. 2024;16(20):3469. doi: 10.3390/nu16203469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Badihi E, Sharifi P, Moradi A, et al. The effect of vitamin D supplementation and vaginal probiotics on fertility in women with recurrent implantation failure: a randomized clinical trial. Hum Immunol. 2025;86(3):111259. doi: 10.1016/j.humimm.2025.111259. [DOI] [PubMed] [Google Scholar]
